Triple

T1169617
Position Surface form Disambiguated ID Type / Status
Subject Ionis Pharmaceuticals E24882 entity
Predicate hasSubsidiaryOrAffiliate P9212 FINISHED
Object Akcea Therapeutics (historical affiliate)
Akcea Therapeutics was a biopharmaceutical company focused on developing and commercializing RNA-targeted therapies for serious rare diseases, historically operating as an affiliate of Ionis Pharmaceuticals.
E24882 NE FINISHED

How this triple was built (5 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Akcea Therapeutics (historical affiliate) | Statement: [Ionis Pharmaceuticals, hasSubsidiaryOrAffiliate, Akcea Therapeutics (historical affiliate)]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Akcea Therapeutics (historical affiliate)
Context triple: [Ionis Pharmaceuticals, hasSubsidiaryOrAffiliate, Akcea Therapeutics (historical affiliate)]
  • A. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • B. Gilead Sciences (board member)
    Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
  • C. Eisai and Biogen
    Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
  • D. Ionis Pharmaceuticals
    Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
  • E. Eli Lilly and Company
    Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Akcea Therapeutics (historical affiliate)
Triple: [Ionis Pharmaceuticals, hasSubsidiaryOrAffiliate, Akcea Therapeutics (historical affiliate)]
Generated description
Akcea Therapeutics was a biopharmaceutical company focused on developing and commercializing RNA-targeted therapies for serious rare diseases, historically operating as an affiliate of Ionis Pharmaceuticals.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Akcea Therapeutics (historical affiliate)
Target entity description: Akcea Therapeutics was a biopharmaceutical company focused on developing and commercializing RNA-targeted therapies for serious rare diseases, historically operating as an affiliate of Ionis Pharmaceuticals.
  • A. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • B. Gilead Sciences (board member)
    Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
  • C. Eisai and Biogen
    Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
  • D. Ionis Pharmaceuticals chosen
    Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
  • E. Eli Lilly and Company
    Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
  • F. None of above.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: hasSubsidiaryOrAffiliate
Context triple: [Ionis Pharmaceuticals, hasSubsidiaryOrAffiliate, Akcea Therapeutics (historical affiliate)]
  • A. hasParentCompany
    Indicates that one company is owned or controlled by another company that serves as its parent organization.
  • B. hasSubsidiaryHistory
    Indicates that an entity has a historical record of owning, controlling, or being associated with one or more subsidiary entities over time.
  • C. hasSubsidiaryTitle
    Indicates that an entity has an additional or secondary title formally associated with its main title.
  • D. hasSisterOrganization
    Indicates that one organization is related to another as a sister organization, typically sharing a common parent, affiliation, or parallel status within the same overarching structure.
  • E. notableSubsidiary chosen
    Indicates that one entity is a subsidiary of another and is particularly significant or prominent among that parent’s subsidiaries.
  • F. None of above.

Provenance (6 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac668562788190ac5f8d081a46b2ee completed March 7, 2026, 5:55 p.m.
NEDg Description generation batch_69ac67a07f28819096fcd7b767e07a63 completed March 7, 2026, 6 p.m.
NED2 Entity disambiguation (via description) batch_69ac6826ef4c81909fc077bfba22b16f completed March 7, 2026, 6:02 p.m.
PD Predicate disambiguation batch_69a4bb5656948190b0b1d5446ad06005 completed March 1, 2026, 10:19 p.m.
Created at: March 1, 2026, 7:45 p.m.